Cancer Blood-Test Startup Guardant Raises Almost $100 Million

  • Investors include OrbiMed, Khosla, Sequoia, Formation 8
  • Company's `liquid biopsies' replace older invasive procedures

Guardant Health Inc. raised almost $100 million in its latest funding round as the startup seeks to expand the use of blood tests to screen for cancer DNA, replacing traditional invasive procedures for tissue samples.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.